NanoViricides Inc. has announced updated employment agreements for two key executives. Dr. Anil R. Diwan will continue as President under a contract extension effective July 1, 2025, and has been granted 10,204 shares of Series A Preferred Stock, vesting quarterly from September 30, 2025, through June 30, 2026. Should Dr. Diwan be terminated without cause, he will receive six months' salary as severance along with continued benefits. Chief Financial Officer Meeta Vyas has also extended her contract for one year starting July 1, 2025, maintaining her monthly base compensation of $10,800 and 129 shares of Series A Preferred Stock per month. Additionally, Ms. Vyas will now be reimbursed for up to 50% of her health insurance costs, capped at $2,500 per month.